CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: A population‐based study in Shanghai, China

Biliary tract cancers, encompassing cancers of the gallbladder, extrahepatic bile duct and ampulla of Vater, are rare but highly fatal malignancies. Other than gallstones, little is known about the risk factors for biliary tract cancers. Endogenous estrogens are thought to play a role in the etiology of gallstones and gallbladder cancer, since both conditions predominate in females and are associated with parity and obesity. In view of reports linking the CYP17 MspA1 polymorphism to high circulating levels of estrogens and a predisposition to other hormonally related cancers, we examined the relationship between CYP17 MspA1 variants and risk of biliary disease in a population‐based case‐control study in Shanghai. The study included 446 cancer cases (254 gallbladder, 139 extrahepatic bile duct, 53 ampullary cancers), 929 biliary stone cases (691 gallbladder, 238 bile duct) and 818 population controls. Genomic DNA from peripheral blood lymphocytes was used for genotyping. Relative to those with the A2/A2 genotype, A1 carriers (A1/A1 and A1/A2 genotypes) had an increased risk of gallbladder cancer (odds ratio (OR) = 1.5, 95% confidence interval (CI) = 1.1–2.1). In addition, women with the A1 allele and high parity (≥3) had a 3‐fold risk of gallbladder cancer (OR = 3.3, 95% CI = 1.6–6.9), compared to those with the A2/A2 genotype and lower parity, with the highest risk seen for those also having biliary stones (OR = 4.6, 95% CI = 1.8–11.7, Pinteraction = 0.04). The A1 allele was not associated with a higher risk of gallstones except among those with body mass index (BMI) greater than 25 kg/m2 (OR = 3.1, 95% CI = 2.0–4.8, Pinteraction = 0.02) and among those with a history of diabetes (OR = 2.5, 95% CI = 1.4–4.3, Pinteraction = 0.09). No clear relation was seen between the CYP17 polymorphism and cancers of the bile duct or ampulla of Vater. The association of the CYP17 MspA1 polymorphism with an increased risk of gallbladder cancer, as well as biliary stones among overweight and diabetic individuals, suggests an interplay between genetic and hormonal risk factors in gallbladder disease. © 2005 Wiley‐Liss, Inc.

[1]  J. Fraumeni,et al.  Aspirin Use and Risk of Biliary Tract Cancer: A Population-Based Study in Shanghai, China , 2005, Cancer Epidemiology Biomarkers & Prevention.

[2]  C. Frampton,et al.  Prevalence of gallbladder disease in diabetes mellitus , 1996, Digestive Diseases and Sciences.

[3]  D. Gertig,et al.  CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study , 2005, Breast Cancer Research.

[4]  A. Tsatsoulis,et al.  Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. , 2003, European journal of endocrinology.

[5]  Jianfeng Xu,et al.  CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population‐based study in China , 2003, International journal of cancer.

[6]  Y. Miyoshi,et al.  Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue. , 2003, Cancer letters.

[7]  S. B. Pedersen,et al.  Estrogen reduces pro-inflammatory cytokines in rodent adipose tissue: studies in vivo and in vitro. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[8]  J. Ioannidis,et al.  Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  E. Bowman,et al.  CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors , 2003, Breast Cancer Research.

[10]  B. Henderson,et al.  Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. , 2002, Mutagenesis.

[11]  C. Kluft,et al.  Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. , 2002, Vascular pharmacology.

[12]  E. Imyanitov,et al.  CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? , 2002, Cancer letters.

[13]  J. Parry,et al.  The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. , 2002, Mutagenesis.

[14]  E. Kuligina,et al.  [Genetic polymorphism of steroid 17 alpha-hydroxylase/17,20-lyase (CYP17) and hyperinsulinemia in endometrial carcinoma]. , 2002, Voprosy onkologii.

[15]  J. Martens,et al.  NF-1C, Sp1, and Sp3 are essential for transcription of the human gene for P450c17 (steroid 17alpha-hydroxylase/17,20 lyase) in human adrenal NCI-H295A cells. , 2001, Molecular endocrinology.

[16]  G. Colditz,et al.  A polymorphism in CYP17 and endometrial cancer risk. , 2001, Cancer research.

[17]  J. Fraumeni,et al.  Beta-catenin mutations in biliary tract cancers: a population-based study in China. , 2001, Cancer research.

[18]  M. Pike,et al.  Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. , 2001, Cancer research.

[19]  S. Erlinger.  Gallstones in obesity and weight loss. , 2000, European journal of gastroenterology & hepatology.

[20]  Y. Miyoshi,et al.  Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. , 2000, European journal of cancer.

[21]  A. Franchitto,et al.  Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. , 2000, Gastroenterology.

[22]  V. Kosma,et al.  Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  M. Karas,et al.  The Potentiation of Estrogen on Insulin-like Growth Factor I Action in MCF-7 Human Breast Cancer Cells Includes Cell Cycle Components* , 2000, The Journal of Biological Chemistry.

[24]  G. Giles,et al.  CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. , 2000, Journal of the National Cancer Institute.

[25]  T. Habuchi,et al.  Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. , 2000, Cancer research.

[26]  M. Stern.  Strategies and prospects for finding insulin resistance genes. , 2000, The Journal of clinical investigation.

[27]  R. Dowling.  Review: pathogenesis of gallstones , 2000, Alimentary pharmacology & therapeutics.

[28]  V. Bhaskaran.  Hormonal receptors in carcinoma of the gallbladder. , 2000, Tropical gastroenterology : official journal of the Digestive Diseases Foundation.

[29]  S. Takagi,et al.  A Review of Cohort Studies on the Association Between History of Diabetes Mellitus and Occurrence of Cancer. , 2000, Asian Pacific journal of cancer prevention : APJCP.

[30]  Howard L. Judd,et al.  Estrogen Replacement Therapy and Gallbladder Disease in Postmenopausal Women , 2000, Menopause.

[31]  J. Fraumeni,et al.  Cancer incidence trends in urban Shanghai, 1972–1994: An update , 1999, International journal of cancer.

[32]  C. Wadelius,et al.  Prostate cancer associated with CYP17 genotype. , 1999, Pharmacogenetics.

[33]  L. Giudice,et al.  The insulin-related ovarian regulatory system in health and disease. , 1999, Endocrine reviews.

[34]  P. Lønning,et al.  CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. , 1999, Cancer research.

[35]  S. Hilsenbeck,et al.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. , 1999, Molecular endocrinology.

[36]  W. Willett,et al.  The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. , 1999, Cancer research.

[37]  I A Malik,et al.  Immuno-histochemical analysis of estrogen receptors on the malignant gallbladder tissue. , 1998, JPMA. The Journal of the Pakistan Medical Association.

[38]  M. Pike,et al.  Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. , 1998, Cancer research.

[39]  J. Fraumeni,et al.  Rising incidence of biliary tract cancers in Shanghai, China , 1998, International journal of cancer.

[40]  M Linet,et al.  Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.

[41]  G. Coetzee,et al.  A polymorphism in the CYP17 gene increases the risk of breast cancer. , 1997, Cancer research.

[42]  S. Curley,et al.  Biliary tract cancer. , 1997, Cancer treatment and research.

[43]  E. Negri,et al.  Menstrual and reproductive factors and biliary tract cancers , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[44]  J. Little,et al.  Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. , 1994, Human molecular genetics.

[45]  S. Runia,et al.  Reproductive history and cancer of the biliary tract in women , 1994, International journal of cancer.

[46]  H. Adami,et al.  Parity and cancers of the gall bladder and the extrahepatic bile ducts , 1993, International journal of cancer.

[47]  M. Johnson,et al.  Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. , 1990, The Journal of biological chemistry.

[48]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[49]  M. Vore.  Estrogen cholestasis. Membranes, metabolites, or receptors? , 1987, Gastroenterology.

[50]  M. Waterman,et al.  Expression of bovine 17 alpha-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. , 1986, Science.

[51]  G. Everson,et al.  Gallbladder function in the human female: effect of the ovulatory cycle, pregnancy, and contraceptive steroids. , 1982, Gastroenterology.

[52]  H. Tiselius,et al.  Effects of postmenopausal ethinylestradiol treatment on gallbladder bile. , 1980, Maturitas.